Articles

The combination of camrelizumab, apatinib, and chemotherapy shows favorable outcomes in the neoadjuvant setting for stage II-III triple-negative breast cancer (TNBC), particularly in patients with programmed death-ligand 1 positivity. Read More ›

The combination of benmelstobart and anlotinib showed a numerical, though not a statistically significant improvement in progression-free survival and overall survival over nab-paclitaxel in recurrent or metastatic triple-negative breast cancer (TNBC). Read More ›

The ASCENT-04/KEYNOTE-D19 trial highlights sacituzumab govitecan plus pembrolizumab as a promising first-line therapy for patients with programmed death-ligand 1 (PD-L1)-positive, advanced triple-negative breast cancer (TNBC). Read More ›

The DeLLphi-304 trial shows tarlatamab significantly improves survival with a manageable adverse-event profile over chemotherapy, establishing a new standard of care for patients with small cell lung cancer (SCLC) after platinum-based chemotherapy. Read More ›

A randomized, phase 2 study found atezolizumab maintenance after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC) did not improve survival outcomes and caused additional toxicities. Read More ›

The IMforte study showed clinically meaningful improvements in progression-free survival and overall survival with lurbinectedin plus atezolizumab compared with atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›

ZG006 demonstrated promising efficacy and a tolerable safety profile in patients with advanced small cell lung cancer, supporting further evaluation in the ongoing phase 2 study. Read More ›